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Previously, we have established one e library by introducing
8 randomized sequences in upper stem and selected out a
series of RNA aptamers with higher afﬁnity to P protein
based on the in vitro SELEX in duck hepatitis B virus
(DHBV) system. Interestingly, we observed that only part of
these stronger binders support priming. In order to explore
structural determinants within e, all selected aptamers
were subjected to RNA structural mapping. We found that
an undamaged bulge is essential for initiating priming.
On the other hand, our study demonstrates that the
stronger binders with damaged bulge structure are able
to be potentially used as decoys for antiviral therapy by
interfering with the protein-priming process of wild type
DHBV. The given data also enable us to understand P-e
interactions during HBV replication in details.
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One of the important factors in safety of blood transfusion
is to use an additional sensitive screening test to identify
blood-born infective agents (like HBV). Although HBsAg
screening reduces the risk of HBV transmission, but HBsAg
negative blood donors may yet transmit HBV infection. The
aim of this study was to assess the possibility of using anti-
HBc as a screening test to improve the detection rate of
HBV infection in donated blood in city of Rasht, North of
Iran.
A total of 2,041 blood samples with negative result for
HBsAg, Anti-HCV, Anti-HIV I, II and RPR were collected
and used to detect anti-HBc Ab. If the result of anti-
HBc was positive, the samples were evaluated for HBVDNA
detection. DNA extraction was done by using a commercial
DNA extraction kit (Qiagen) and analyzed using a commercial
quantitative real-time PCR kit (artus HBV LC PCR Kit). The
positive sample was rechecked with a reliable and sensitive
homemade PCR kit.
The prevalence of anti-HBc Ab positive was 78/2041
(0.038%) by total anti-HBc Ab kit. One out of 78 anti-HBc Ab
positive sample was positive for HBVDNA when was checked
by real-time PCR and re-checked by homemade kit.
This study showed that the anti-HBc Ab positivity is lower
than many parts of Iran in Rasht. As anti-HBc Ab positive
blood donors may be a potential source of HBV transmission
further study for evaluation of HBVDNA in anti-HBc positive
blood units is strongly recommended.
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Background and Aims: The experimentation of antivirals,
new vaccine formulations and adjuvanted antigens, able to
elicit a speciﬁcally targeted cellular response or to interfere
with viral replication to break tolerance, is crucial for
immunotherapeutic approaches of Hepatitis B Virus (HBV)
infection. In this study we have applied the well recognized
preclinical model of the HBV, the Woodchuck (Marmota
monax) chronically infected from Woodchuck Hepatitis Virus
(WHV) with the aim to investigate the neutralization and
antiviral effects of Immune Genic Complex (IGC) composed
by preS/S antibodies and WHV particles in healthy and in
WHV chronically infected animals.
Methods: The characterized and quantiﬁed neutralization
mixture or IGC, was intravenously and intradermically
administered to four WHV negative and ﬁve WHV chronic
carriers. One animal was used as infection control.
Electro-chemi-luminescence immuno-assay (Elecsys, Roche
Molecular Diagnostics) to detect antibody to WHV core
antigen (WHcAb) and WHV “e” antigen (WHeAb), and
WHV “e” antigen (WHeAg) was used. WHV Real-Time PCR
was applied to determine the viral load every two weeks
after IGC administrations and PBMc proliferation assays was
performed making use of Core and PreS/S HBV regions
epitopes.
Results: The IGC administration obtained with the lowest
preS/S antibody amount (2.5mIU) showed, in WHV negative
woodchucks, better neutralization effects in terms of
WHeAg and viral load concentrations in all treated animals
in respect to the controls. The IGC administration in WHV
chronic carriers induced strong antiviral effect in three
out of ﬁve animals. The viral phylogenetic analysis (MEGA 4
program) of PreS/S region showed, in one animal, signiﬁcant
variation during follow up.
Conclusions: This newly designed experimental protocol
will be at the basis for further developments in the ﬁeld
of improvement of antigenic adjuvancy and of therapeutic
vaccines formulations.
PP-014 Entecavir treatment of chronic hepatitis B
patients who are exposed to lamivudine
R. Behal *, P. Upadhyay, P. Srivastava, T.S. Negi,
G. Choudhuri. Department of Gastroenterology, Sanjay
Gandhi Post Graduate Institute of Medical Sciences,
Raebareli Road, Lucknow, 226014, India
Background and Aims: In treatment of naive chronic
hepatitis B (CHB) patients, Entecavir shows good long term
viral suppression and low rate of development of resistance.
Its role in patients of CHB, who are exposed to lamivudine
therapy, is not clear. We studied the efﬁcacy of Entecavir
in this group of patients.
Methods: Ten patients who showed breakthrough
during lamivudine therapy, were treated with Entecavir
(1mg/day). The dose was modiﬁed in patients of renal
failure as required. HBVDNA quantitative levels were
done 3 monthly to assess adequacy and duration of viral
suppression. Assessment for Entecavir resistance deﬁned as
decline of <1 log10 copies/ml in 12 weeks or increase in
HBVDNA by 1 or 2 log levels were the primary end points.
Results: Of 10 patients (8 male; 8 HBeAg positive,
5 with compensated Liver Cirrhosis) who received Entecavir,
phenotypic resistance to Entecavir was seen in 5 (50%) over
a mean period of 12± 4.58 months. Of these 5, 4 were
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on 1.0mg/day dose. Median follow up of patients was:
11.5± 4.13 months (1.0mg dose) and 9.25± 4.78 months
(0.5mg dose). Four of six patients (66%) who received
1mg/day Entecavir, developed resistance over a median
follow up of 11 months. Of the four patients who received
0.5mg/day entecavir, one (25%) developed resistance over
follow up of 15 months.
Conclusions: Entecavir therapy in Lam resistant CHB
patients was associated with a high rate of inadequate
viral suppression and development of resistance. The dose
of Entecavir (0.5 or 1.0) did not seem to have much effect
in this group of patients.
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Background: Resistance to CHB antivirals is a challenge
in the long term. Clinical beneﬁts are compromised once
resistance develops and cross-resistance limits treatment
options.
Methods: Current study randomly selected 575 CHB-treating
physicians from China, South Korea, Taiwan, and Thailand
where HBV infection is a substantial clinical and ﬁnancial
burden. The study comprised two components designed to
assess: (1) current practice in diagnosing antiviral resistance
and its management; and (2) ﬁnancial impact of managing
“suspected” resistance.
Results: 95 100% of interviewed physicians had encountered
antiviral resistance in the ﬁrst-line setting. Although 68%
agreed that prevention of resistance is the most important
strategy, 5% did not consider resistance a critical issue.
While direct antiviral resistance tests are readily available
in South Korea, access is limited in most Asian countries.
DNA and ALT tests are the common parameters used
to identify suspected resistance in China, Taiwan, and
Thailand. Management of suspected resistance (drug cost
not included) costs an additional USD 709, 580, 572 and 329
in South Korea, China, Taiwan and Thailand respectively,
during the ﬁrst year immediately after it is identiﬁed.
Conclusion: Antiviral resistance is a major concern among
physicians in Asia, especially during long-term therapy.
While access to direct resistance testing is limited in most
countries, indirect methods are widely used to guide CHB
management decisions. In choosing an oral antiviral to
initiate therapy, resistance proﬁle of antiviral is a crucial
factor to consider since drug resistance compromises clinical
beneﬁt and incurs additional cost.
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Objective: The aim of this study is to investigate the
viral and host factors of metabolic syndrome in chronic
hepatitis B patients.
Methods: We studied 89 patients with untreated chronic
hepatitis B, who were from Beijing Ditan hospital in 2005 to
2007. According to the diagnose of metabolic syndrome, two
groups were established: group with MS (+MS) and group MS
( MS).They were compared with demographic, biochemical,
metabolic and histological characteristics.
Results: The mean age, BMI and gender were not
statistically signiﬁcant difference (p > 0.05) between the
two groups. In the group of chronic hepatitis B with MS,
the levels of FINS, HOMA-IR, HOMA-b, TG, and the positivity
of HBeAg were signiﬁcantly higher than those in the group
without MS (P< 0.05. The degree of hepatosteasis in the
group with MS is signiﬁcantly more severe than that in the
group without MS (P< 0.001).
Conclusion: Metabolic syndrome in chronic hepatitis B
patients is closely correlated with insulin resistance and
glycometabolism, and less effect of viruses. That may be the
main characteristic of metabolism in patients chronically
infected with the hepatitis B virus.
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Objective: This paper is an attempt to do research on
the cloning characteristics of the CDR3-distinct of the TCR
Vbgene of the CD8+T cell of the HBV infected person.
Methods: The PCR approach of poly-primer is applied and
meanwhile the many pieces of the CDR3-distinct of the TCR
Vb gene are ampliﬁed. HR-Agarose Gel Electrophoresis is
employed to detect the cloning characteristics.
Result: The HBV infected person’s cloning of the TCR Vb9
and Vb14 of the CD8+T cell is obviously higher than the
normal control group (p < 0.01).
Conclusion: The HBV infected person has the cloning
changes of the TCR VbandVb14 of the CD8+T cell, which
have an effect on the mediating of the Liver Injury.
PP-018 HIV/Hepatitis B Co-infection among Nepal
MSM/W
S. lal Acharya1 *, A. Sitoula Trisuli Plus2, S. Lama2,
G. Maharjan3. 1White Feather Nepal, 2National Association
of PLHA in Nepal (NAP+N), 3Tribhuvan University,
Department of Heath and social science, Katmandu,
Nepal
HIV/AIDS is one of the most public health problems of
this century. Moreover, co-infection with the Hepatitis B
virus is likely to become a major health care catastrophe.
This study was carried out White Feather Nepal and
different 4 Laboratories with the objective to determine
HIV/Hepatitis B co-infection among 544 sexual minorities
from Katmandu including Men Sex workers, gay men and
transgender.
Methods: HIV status was determined both by Rapid and
ELISA techniques. HIV sero-positive samples were further
tested for Hepatitis B Surface Antigen (HBsAg) by ELISA.
Data obtained from laboratories ﬁndings and questionnaires
were statistically analyzed by using SPSS 11.5.
Results: Out of 544 HIV suspected individuals, 221 (40%)
were diagnosed as HIV positive, of which, 187 HIV positive
sera were tested for Hepatitis B. In HIV positive individuals,
sexual transmission was the most common route (77.4%),
followed by IDUs (12.2%). Of 187 HIV positive individuals,
15% were diagnosed to be co-infected with Hepatitis B.
Highest prevalence of HIV/Hepatitis B co-infection (46.4%)
was observed in age group 26 35 years, followed by 16 25
years and the co infection rate was found to be higher
(78.6%) in married individuals than in unmarried (17.9%).
Lower rate of co-infection (17.9%) was detected among the
individuals vaccinated against Hepatitis B than unvaccinated
(82.1%).
